Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients.

"Conflict of interest: The study was supported by Novartis, which was the data controller of the study. D. Kamar and C. Thonnelier are employees of Novartis. Novartis was involved in the study design, data analysis, decision to publish and preparation of the manuscript. D. Kamar additionally reports consulting fees and support for attending meetings from Ividata Life Sciences providing services for Novartis. A. Lajoinie and A. Rigault are employees of RCTs. RCTs did not fund the study but was in charge of designing and performing the study as data processor. A. Rigault was an employee of the French health insurance until 1 September 2020. M. Humbert, A. Bourdin, C. Taillé, A. Deschildre and M. Molimard received honoraria paid by Novartis as members of the study Independent Scientific Committee. M. Humbert also reports consulting fees from AstraZeneca, Chiesi, GSK, Novartis and Sanofi; lecture honoraria from AstraZeneca, GSK, Novartis and Sanofi; outside the submitted work. A. Bourdin and C. Taillé also report lecture honoraria from AstraZeneca, Chiesi, GSK, Novartis and Sanofi; outside the submitted work. A. Deschildre also reports grants from Fondation du Souffle; Conseil Régional Hauts-de-France program 2014–2018 (grant ARCiR 2015-284); consulting fees from Novartis, ALK, GSK, Sanofi, Regeneron, Aimmune Therapeutics, DBV Technologies, Nestlé Health Science and Stallergenes Greer; lecture honoraria from Novartis, ALK, GSK, Sanofi, Aimmune Therapeutics, DBV Technologies, Nestlé Health Science and Boehringer Ingelheim; support for attending congresses from ALK, Sanofi, Boehringer Ingelheim, Stallergenes Greer, Novartis, AstraZeneca, Meda, DBV Technologies, Aimmune and Nutricia; acted on the Data Safety Monitoring Board (DSMB) for the BOOM study (ClinicalTrials.gov identifier: NCT04045301; Lead Investigator: Philippe Bégin, Montreal, QC, Canada); outside the submitted work. M. Molimard also reports consulting fees from Novartis and Stallergenes; participation on advisory board for Banook; outside the submitted work."

"Conflict of interest: The study was supported by Novartis, which was the data controller of the study. D. Kamar and C. Thonnelier are employees of Novartis. Novartis was involved in the study design, data analysis, decision to publish and preparation of the manuscript. D. Kamar additionally reports consulting fees and support for attending meetings from Ividata Life Sciences providing services for Novartis. A. Lajoinie and A. Rigault are employees of RCTs. RCTs did not fund the study but was in charge of designing and performing the study as data processor. A. Rigault was an employee of the French health insurance until 1 September 2020. M. Humbert, A. Bourdin, C. Taillé, A. Deschildre and M. Molimard received honoraria paid by Novartis as members of the study Independent Scientific Committee. M. Humbert also reports consulting fees from AstraZeneca, Chiesi, GSK, Novartis and Sanofi; lecture honoraria from AstraZeneca, GSK, Novartis and Sanofi; outside the submitted work. A. Bourdin and C. Taillé also report lecture honoraria from AstraZeneca, Chiesi, GSK, Novartis and Sanofi; outside the submitted work. A. Deschildre also reports grants from Fondation du Souffle; Conseil Régional Hauts-de-France program 2014–2018 (grant ARCiR 2015-284); consulting fees from Novartis, ALK, GSK, Sanofi, Regeneron, Aimmune Therapeutics, DBV Technologies, Nestlé Health Science and Stallergenes Greer; lecture honoraria from Novartis, ALK, GSK, Sanofi, Aimmune Therapeutics, DBV Technologies, Nestlé Health Science and Boehringer Ingelheim; support for attending congresses from ALK, Sanofi, Boehringer Ingelheim, Stallergenes Greer, Novartis, AstraZeneca, Meda, DBV Technologies, Aimmune and Nutricia; acted on the Data Safety Monitoring Board (DSMB) for the BOOM study (ClinicalTrials.gov identifier: NCT04045301; Lead Investigator: Philippe Bégin, Montreal, QC, Canada); outside the submitted work. M. Molimard also reports consulting fees from Novartis and Stallergenes; participation on advisory board for Banook; outside the submitted work. Support statement: This work was supported by Novartis Pharma. Funding information for this article has been deposited with the Crossref Funder Registry."